74 completed. 74 Phase 1, 28 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 74 | Completed 74 |
| Phase 2 | 28 | Completed 28 |
Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine SARS-CoV-2 Protein Subunit Recombinant Vaccine, SARS-CoV-2 Inactivated Vaccine - Covid19 | Phase 1 | Completed | PT Bio Farma | 54 | 2021-12-10 | 2022-08-09 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19 Angiotensin Converting Enzyme 2, Sodium chloride - Covid19 | Phase 1 | Completed | Apeiron Biologics | 40 | 2021-10-19 | 2022-09-23 |
| Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection Cytotoxic T Lymphocytes - Covid19 | Phase 1 | Completed | Thomas Jefferson University | 30 | 2021-09-15 | 2025-04-29 |
| Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers AdCLD-CoV19-1 - Covid19 | Phase 1 | Completed | Cellid Co., Ltd. | 40 | 2021-09-09 | 2023-07-28 |
| Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant - SARS-CoV Infection, Covid19 | Phase 1 / Phase 2 | Completed | Novavax | 637 | 2021-09-08 | 2025-04-10 |
| Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40 - Covid19, SARS CoV 2 Infection | Phase 1 / Phase 2 | Completed | Laboratorios Hipra, S.A. | 30 | 2021-08-16 | 2023-03-01 |
| Study of PBI-0451 in Healthy Subjects. PBI-0451 Dose 1, PBI-0451 Dose 2, PBI-0451 Dose 3 - Covid19 | Phase 1 | Completed | Pardes Biosciences, Inc. | 130 | 2021-08-14 | 2022-06-03 |
| Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Recombinant SARS-CoV-2 Fusion Protein Vaccine - COVID19 | Phase 1 | Completed | Livzon Pharmaceutical Group Inc. | 43 | 2021-08-07 | 2023-04-25 |
| Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents CVXGA1 low dose, CVXGA1 high dose - Covid19 | Phase 1 | Completed | CyanVac LLC | 72 | 2021-08-06 | 2024-02-07 |
| Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 Sacubitril / Valsartan Oral Tablet [Entresto], Placebo - Covid19 | Phase 1 / Phase 2 | Completed | Duke University | 42 | 2021-08-06 | 2024-07-03 |
| A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID) Ampion, Placebo - Covid19 | Phase 1 | Completed | Ampio Pharmaceuticals. Inc. | 32 | 2021-07-26 | 2023-09-21 |
| Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 MVA-SARS-2-ST - Covid19 | Phase 1 | Completed | Universitätsklinikum Hamburg-Eppendorf | 43 | 2021-07-16 | 2023-01-18 |
| A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants sotrovimab, Placebo to Biologic - Covid19 | Phase 1 | Completed | Vir Biotechnology, Inc. | 48 | 2021-07-06 | 2024-06-07 |
| RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19 mQFPD, organic brown rice - Covid19 | Phase 1 | Completed | University of California, San Diego | 60 | 2021-07-01 | 2025-09-05 |
| A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers SC-Ad6-1 - Covid19 | Phase 1 | Completed | Moat Biotechnology Corporation | 196 | 2021-06-28 | 2025-08-21 |
| Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine QazCoVac-P -COVID-19 Subunit Vaccine, Placebo - Covid19, SARS-CoV Infection | Phase 1 / Phase 2 | Completed | Research Institute for Biological Safety Problems | 244 | 2021-06-15 | 2023-12-07 |
| Enriched Heparin Anti COVID-19 Trial Heparin sodium, Placebo - Covid19 | Phase 1 / Phase 2 | Completed | UPECLIN HC FM Botucatu Unesp | 27 | 2021-06-01 | 2024-10-15 |
| Menstrual Blood Stem Cells in Severe Covid-19 Allogeneic human menstrual blood stem cells secretome, Intravenous saline injection - Covid19, Cytokine Storm | Phase 1 / Phase 2 | Completed | Avicenna Research Institute | 29 | 2021-04-17 | 2021-09-02 |
| Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study AKS-452 - Covid19 | Phase 1 / Phase 2 | Completed | University Medical Center Groningen | 112 | 2021-04-06 | 2024-04-16 |
| Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19 Aerobic Exercise Therapy - Covid19, Coronavirus | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2021-03-29 | 2025-10-27 |
Showing 20 of 74. Sign in to see all of them.
COVID-19 (74) · Coronavirus Infections (10) · Severe Acute Respiratory Syndrome (7) · Pneumonia (3) · Respiratory Distress Syndrome (3) · Pneumonia, Viral (2) · Acute Lung Injury (1) · Communicable Diseases (1) · Cytokine Release Syndrome (1) · Motor Activity (1) · Multiple Organ Failure (1) · Muscle Weakness (1) · Muscular Atrophy (1) · Neoplasms (1) · Thrombosis (1)
Coronaviridae Infections (74) · Infections (74) · Lung Diseases (74) · Nidovirales Infections (74) · RNA Virus Infections (74) · Respiratory Tract Diseases (74) · Respiratory Tract Infections (74) · Virus Diseases (74) · Pneumonia, Viral (72) · Pneumonia (71) · Coronavirus Infections (64) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Respiration Disorders (3) · Shock (2)
Ivermectin (4) · Standard of Care (3) · Single Person (2) · aspartyl-alanyl-diketopiperazine (2) · ABNCoV2 vaccine (1) · AKS-452 COVID-19 vaccine (1) · Acetylglucosamine (1) · AdCLD-CoV19-1 vaccine (1) · Angiotensin-Converting Enzyme 2 (1) · BNT162 Vaccine (1) · COVID-19 Nucleic Acid Testing (1) · COVID-19 Serotherapy (1) · CVXGA1 COVID-19 vaccine (1) · Carrageenan (1) · Electric Stimulation (1)
Ampio Pharmaceuticals. Inc. (2) · Research Institute for Biological Safety Problems (2) · University Medical Center Groningen (2) · Universitätsklinikum Hamburg-Eppendorf (2) · Alkarkh Health Directorate-Baghdad (1) · Amorphical Ltd. (1) · Apeiron Biologics (1) · Avicenna Research Institute (1) · Bausch Health Americas, Inc. (1) · Baylor College of Medicine (1) · BeiGene (1) · Biomad AS (1) · BonusBio Group Ltd (1) · Cellenkos, Inc. (1) · Cellid Co., Ltd. (1)
United States (22) · Australia (6) · Russia (5) · Israel (4) · Canada (3) · Netherlands (3) · Argentina (2) · Brazil (2) · China (2) · Germany (2) · Indonesia (2) · Iraq (2) · Kazakhstan (2) · South Korea (2) · Turkey (Türkiye) (2)
Marylyn M Addo, MD (2) · Ali Dehghan-Manshadi, MD (1) · Anya Loncaric (1) · Barry Bratcher (1) · Berik Khairullin, PhD (1) · Cheng Yao (1) · Christian Gaebler, MD (1) · Daria Mochly-Rosen, PhD (1) · Dr. Muhammad Karyana, MPH (1) · Duncan J Stewart, MD (1) · Elia Torroella (1) · Erdal Karaoz, Prof.Dr. (1) · Eric Salazar, MD, PhD (1)
PMID 34473343, PMID 39749328, PMID 27344959, PMID 32251768, PMID 32423449, PMID 32555388, PMID 33845867, PMID 33887208, PMID 34306677, PMID 34346827, PMID 34414368, PMID 34775578, PMID 34980198, PMID 35115195, PMID 35255966, PMID 35365239, PMID 35511920, PMID 35720389, PMID 35816490, PMID 36104785, PMID 36435633, PMID 36561714, PMID 36681093, PMID 36842886, PMID 37775521, PMID 37865043, PMID 37955825, PMID 38375429, PMID 38733160, PMID 38885482, PMID 39191809, PMID 39892108, PMID 40248705, PMID 41106035, PMID 41644167